Skeletal Muscle Wasting in ICU Patients
Launched by FRANK VANDENABEELE · Jan 30, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how muscle wasting happens in critically ill patients who are in the intensive care unit (ICU). When patients are very sick, their bodies often break down muscle faster than they can build it back up, leading to significant muscle loss. The researchers want to measure how quickly muscle protein is made during a week in these patients and understand the changes at a microscopic level that lead to muscle wasting. They also plan to see if muscle size improves three months after the patients leave the ICU.
To participate in this study, you need to be an adult over 18 years old who is currently in the ICU and expected to stay for more than seven days. You should have a feeding tube in place and an arterial line for monitoring. However, if you have certain conditions like chronic kidney or liver failure, or are using specific medications, you may not be eligible. If you join the study, you can expect to give some information about your health, and you may take part in tests that help researchers understand muscle recovery during your stay in the ICU and beyond.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age \>18y
- • admitted to ICU
- • enteral nutrition line in situ
- • arterial line (any location) in situ
- • expected stay ICU \>7d
- Exclusion Criteria:
- • spinal cord injury
- • chronic use of corticosteroids before hospital admission
- • Contraindication to enteral infusion (e.g. due to GI-tract perforation)
- • Kidney or liver failure
- • therapeutic anti coagulation
About Frank Vandenabeele
Frank Vandenabeele is a distinguished clinical trial sponsor specializing in innovative research and development in the healthcare sector. With a commitment to advancing medical science, the organization focuses on designing and executing clinical trials that adhere to the highest ethical and regulatory standards. Leveraging a robust network of industry partnerships and a team of experienced professionals, Frank Vandenabeele aims to facilitate the discovery and delivery of novel therapies that improve patient outcomes. Their dedication to transparency and collaboration underscores a mission to contribute significantly to the advancement of medical knowledge and treatment options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hasselt, Limburg, Belgium
Patients applied
Trial Officials
Frank Vandenabeele, Prof.
Principal Investigator
Hasselt University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported